354 results about "Diagnostic marker" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention provides an electroencephalogram data transmission method combining lossless and lossy compression, belongs to the field of electroencephalogram data transmission and compression processing, and is used for solving the problems of low transmission efficiency of pure lossless compression and easy loss of key diagnosis information of pure lossy compression in related technologies. According to the method, multi-dimensional features of electroencephalogram data are extracted, a key area and a non-key area are divided, lossless compression and lossy compression processing are adopted respectively, the area division proportion is dynamically adjusted in combination with transmission bandwidth, signal features and application scenes, and corresponding data are transmitted through dual protocols. The transmission efficiency can be improved while the clinical diagnosis marker and the core characteristics are reserved, and the scene adaptability and the transmission reliability are achieved at the same time.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

The invention provides an application of human source circular RNA hsacirc0083796 in preparation of a diagnostic reagent or a medicine for diagnosing and / or treating aortic dissection. The invention also provides a kit for diagnosing the aortic dissection. The invention also provides a pharmaceutical composition for treating aortic dissection. According to the application of the human source circular RNA in preparation of heart disease related products, the related heart disease related circular RNA (circled-Frizzled class receptor 3, hsacirc0083796) is one of circular RNAs with the highest expression quantity in the blood of aortic dissection patients and has high conservative property, the function of the circular RNA is closely related to heart diseases, and the circular RNA has a good application prospect in preparation of heart disease related products. The method has great significance in diagnosis and treatment of heart diseases. Meanwhile, due to the stable and specific properties of the circular RNA, compared with other types of markers, the circular RNA has larger abundance in body fluid of a patient and more obvious change, so that the circular RNA has the potential of becoming a novel diagnostic marker.

A method of automatically diagnosing pneumonia in a patient includes obtaining values of two or more diagnostic parameters of the patient from a caregiver of the patient using an input / output interface device. The method includes applying, using a processor connected to an input / output interface, two or more diagnostic parameters to an electronic memory storing a plurality of pre-compiled pneumonia diagnostic models to identify an optimal diagnostic model for performing the diagnosis. The values of the two or more diagnostic markers are applied to the identified optimal diagnostic model to generate a diagnostic output. An input / output interface device is operated according to the diagnostic output to indicate to the caregiver the presence or absence of pneumonia in the patient. The caregiver may use the diagnostics to provide appropriate care for the patient. A pneumonia diagnostic model is from investigations of pneumonia-positive and non-pneumonia population of subjects.

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

The present invention discloses an application of a long non-coding RNA in serum exosomes as a diagnostic marker for non-small cell lung cancer, characterized in that the long non-coding RNA is the AL139294.1 gene, and its nucleotide sequence is shown in SEQ ID NO.1; the application of the non-small cell lung cancer diagnostic marker in the preparation of a molecular targeted drug for non-small cell lung cancer or a non-small cell lung cancer diagnostic kit, wherein the diagnostic kit comprises a pair of specific amplification primers for detecting the expression amount of the lncRNA AL139294.1 gene in serum exosomes, and the specific nucleotide sequences are as follows: upstream amplification primer: 5'-TGTCACAGCAGATGCCACA T-3'; downstream amplification primer: 5'-CCCACTCGCTGCCTATAACA-3'; the advantages are high sensitivity and specificity and positive correlation with the prevalence of non-small cell lung cancer.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The invention discloses a colorectal cancer diagnostic marker group based on expiration volatile organic compounds and application of the colorectal cancer diagnostic marker group. The colorectal cancer diagnostic marker group consists of six expiration volatile organic compounds, namely furfural, 2-methyl butane, valeric acid, methyl allyl sulfide, hexane and octanal. According to the method, expiration samples of 182 subjects are analyzed through TD-GC-MS / MS, machine learning is combined, the six expiration volatile organic compounds are screened out, the diagnosis AUC of the combination in a verification queue reaches 0.907, the accuracy rate is 0.806, and the combination is superior to a serum marker combination (AUC = 0.861). The invention further provides the BRS and a colorectal cancer noninvasive diagnosis and risk stratification system, and the BRS and the colorectal cancer noninvasive diagnosis and risk stratification system are used for achieving efficient prediction and risk stratification of the colorectal cancer. Compared with a traditional risk scoring model depending on clinical variables such as age, family history and lifestyle, the BRS provides unique metabonomics information, and the prediction accuracy is remarkably improved.

The present invention discloses a set of diagnostic markers for aortic dissection and their applications. The markers include the genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2. The genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2 protected by the present invention can be used as biomarkers for AD and as indicators for assessing disease severity in AD patients, enabling efficient diagnosis of patients with aortic dissection.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnostic marker for lung transplantation rejection and application of the diagnostic marker. The invention discloses one or more of OIT3, CAMP, USP4, IPO9 and PON1 as markers for diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the markers. The invention discloses that the OIT3 can be used as a diagnosis and treatment target of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the OIT3; the lung transplantation rejection reaction can be prevented and / or treated through the OIT inhibitor.

The invention discloses a gene marker for diagnosing latent tuberculosis infection and application of the gene marker, and belongs to the technical field of biological medicine. According to the present invention, the latent tuberculosis infection early diagnosis marker is screened based on the peripheral blood whole genome DNA methylation map, the new target is provided for the diagnosis of latent tuberculosis infection, the diagnosis efficiency of the marker is evaluated through pyrosequencing, the corresponding detection kit and the use method are developed, and the rapid and accurate diagnosis of latent tuberculosis infection is achieved.

The invention relates to the technical field of biology, and particularly discloses application of LLPH as a lung cancer diagnosis biomarker and a treatment target spot, an LLPH expression inhibitor is an LLPH gene knockout plasmid and a genetic engineering construct containing sgRNA and a carrier, the LLPH expression inhibitor is suitable for CRISPR / Cas system mediated gene editing, the sgRNA sequence is 5 '-CTAAAGCTTACGGAGTAAG-3', the carrier is pX459M, and the enzyme cutting site is BbsI-BbsI; by detecting the relative expression quantity of LLPH in normal lung bronchial epithelial cells and lung cancer cell lines, it is found that LLPH is highly expressed in the lung cancer cell lines, and it is shown that LLPH is closely related to lung cancer development. The invention can provide a new biomarker for diagnosis of lung cancer. Lung cancer A549 and H1299 cells are used as models, and the LLPH gene is knocked out, so that the in-vitro malignant proliferation capacity of the lung cancer cells A549 and H1299 can be remarkably inhibited, and LLPH can be used as a potential treatment target for inhibiting lung cancer proliferation.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The present invention discloses an EBV-related gastric cancer diagnostic marker and its application, wherein the diagnostic marker is selected from at least one of LF2 protein and BFRF3 protein. The present invention is the first to screen and obtain two diagnostic markers for EBV-related gastric cancer (EBVaGC) based on proteome chips and phage display technology - LF2 protein and BFRF3 protein, which can efficiently and accurately diagnose EBVaGC. In particular, the AUC of the combined diagnosis of these two proteins can reach 0.911, which is significantly better than the AUC of the individual diagnoses. And when diagnosing EBVaGC based on these two proteins, no tissue sample is required, only a serum sample is required, and it can be detected during a routine blood test. Therefore, compared with existing diagnostic methods, the present invention has the characteristics of high accuracy, small limitations, and low cost, reduces the cost of medical treatment for patients, is conducive to the realization of universal screening of the population, simplifies the diagnosis process of EBVaGC, and significantly improves the treatment efficiency.

The application provides a diagnostic marker for rheumatoid arthritis, a detection chip and application thereof, and belongs to the technical field of disease diagnosis.The diagnostic marker for rheumatoid arthritis provided by the application comprises at least one of the following antibodies: an anti-ANAPC15 antibody, an anti-LSP1 antibody, an anti-APBB1 antibody, an anti-parathymosin antibody and an anti-UBL7 antibody.The specific antibody for rheumatoid arthritis provided by the application is used as a diagnostic marker based on the above scheme, and the target antibody in the serum to be detected is detected by using the specific binding property of the antigen and the antibody.The immune chip provided by the application is simple to operate, and can complete the detection of the diagnostic marker with high throughput, high efficiency and high accuracy, has the characteristics of low cost and rapid detection, and is suitable for market promotion and application.

The invention discloses a colon cancer diagnostic marker screening method and system based on transcriptome data, and belongs to the technical field of biological information, and the method comprises the steps of data preparation, pathological hierarchical modeling, diagnostic marker screening and screening report generation. According to the method, pathological hierarchical modeling based on dynamic discrimination and double-layer feature fusion is adopted, on the basis of comprehensively considering gene expression and pathological morphology information, pathological subtypes of colon cancer samples are adaptively recognized, stable and representative subtype features are obtained, and therefore the accuracy and biological representativeness of diagnostic marker screening are improved; diagnostic marker screening based on pathological subtype difference analysis is adopted, and on the premise of considering pathological subtype characteristics, a stable and reliable diagnostic marker set with remarkable expression difference is screened in a targeted manner, so that the biological representativeness, screening robustness and diagnostic specificity of markers are improved.

The invention belongs to the technical field of gene editing and disease model construction, and particularly relates to a construction method and application of a Wilson disease animal model. Aiming at a large fragment deletion mutation type which exists clinically in Wilson disease but lacks a corresponding animal model, a CRISPR / Cas9 gene editing technology is utilized, a pair of sgRNAs is specifically designed, an eighth exon region of a mouse Atp7b gene is precisely cut and deleted, and a WD mouse model with deletion mutation (c.2333340delGACGGTGG) of eight basic groups of the eighth exon of the Atp7b gene is successfully constructed. The method can be used for research on pathogenesis of WD, screening of novel diagnostic markers and evaluation of curative effect of therapeutic drugs, is particularly suitable for preclinical evaluation of gene therapy strategies and development of adjuvant therapeutic drugs of targeted NLRP3 inflammasomes, and has great scientific research value and clinical transformation prospect.

The invention belongs to the technical field of diagnosis and treatment of osteosarcoma, and particularly relates to application of a C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis in diagnosis and treatment of osteosarcoma, a full-chain technical system of'diagnostic marker-double-target intervention-clinical transformation 'is constructed on the basis of the C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis, and accurate diagnosis and metabolic intervention of osteosarcoma are realized through multi-dimensional experimental verification; in the diagnosis, a C1QTNF1-AS1 / miR-346 combined detection kit based on qPCR is applied to early screening of osteosarcoma; according to the treatment application, the C1QTNF1-AS1 adenovirus and the miR-346 lipidosome are used in a combined manner, and LDHA and PDK1 are synchronously inhibited, so that the Warburg effect related metabolic flux is intervened.

The present disclosure relates to a cell-free DNA-based cancer diagnosis model and use. A first aspect of the present disclosure provides a construction method for a cancer diagnosis model, including the steps of obtaining sequencing data of cell-free DNA of a non-cancer population; comparing the sequencing data of the cell-free DNA of the non-cancer population with reference genomes to obtain corresponding sites of the ends of the cell-free DNA on the reference genomes; and constructing the cancer diagnosis model based on the corresponding sites of the ends of the cell-free DNA on target genome intervals. The present disclosure adopts an idea that is opposite to the prevailing method. Instead of trying to identify diagnostic markers based on the specific fragmentation patterns of tumor cfDNA, the applicant constructs the cancer diagnosis model by looking for the end distribution patterns of cfDNA in non-cancer population.